News

The 340B program has had a great impact on access to HIV treatment and prevention services in the US.

Patients who contracted COVID-19 later in the pandemic (2021-2022) were more likely to develop new chronic diseases after infection than patients who caught COVID-19 in 2020.

A key stakeholder offers his insights on the importance of the new Biden plan to eliminate hepatitis C as well as the federal strategy to get more people linkage to care for hepatitis B.

Anemia is both common and independently associated with poor clinical outcomes in respiratory infections, including COVID-19.

Increased understanding of HCV protective immunity and HCV envelope glycoprotein structure and function may propel development of an HCV vaccine.

The FDA moved to harmonize primary and booster COVID-19 vaccine doses, deciding only the Moderna and Pfizer-BioNTech bivalent mRNA vaccines should be administered to individuals 6 months and older.

The FDA’s Antimicrobial Drugs Advisory Committee (AMDAC) voted 12-0 in favor of recommending this antibiotic and sets up a PDUFA target action date of May 29.

Since the lifting of public health restrictions, the country saw a sizable increase in incidence rates.

Post-COVID-19 conditions were more common in unvaccinated children than in children who had received at least 1 dose of a COVID-19 vaccine.

Poor sleep quality, deterioration in sleep quality, and sleep regularity were all linked to impaired lung function.

Several years after its FDA approval, this antibiotic continues to prove its efficacy in vitro across various pathogens related to these infections.

Alita Miller, PhD, senior vice president of research at Entasis Therapeutics, discusses positive trial data for Sulbactam-durlobactam (SUL-DUR) slated to be presented at ECCMID 2023.

A new study presented at the European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) examined a rapid cellular host response test designed to aid providers who are working in emergency departments and need quick, efficient diagnostic information.

Catch up with this week's 5 most-read infectious disease stories.

These study findings suggest COVID-19 admission testing may not be necessary in hospitals, as most asymptomatic COVID-19 patients were not infectious.

People with COVID-19 who were hospitalized had a slightly higher rate of death than those with influenza. However, there were considerably more severe COVID-19 cases than the flu, leading to a much higher number of overall deaths associated with SARS-CoV-2.

With limited amounts of antibacterials, prescribers are presented with optimal therapy challenges as well as difficulties in trying to achieve stewardship.

Reducing unnecessary antibiotic prescriptions for viral upper respiratory tract infections is crucial to stop the spread of antimicrobial resistance.

The R21/Matrix-M vaccine can now be used in Ghana and could help in the prevention of a vector-borne disease that kills over 600,000 people annually.

2 CDI recurrences occurred in this study, both in placebo recipients who were immunocompromised.

The Veterans Administration reported a reduction in the bacterial infection in healthcare settings where infection prevention practices were continued.

This study implemented an Electronic Health Record in a major hospital system to catch otherwise undetected C diff infections.

The epidemiology society worked with a few medical organizations to update the guidance to limit infections.

The investigators compared sources of antibiotic resistant genes in human, animal, soil, water/sediment, and wastewater treatment plants.

A study looking at 5 years of data showed a decrease in the amount of cases, but with some important trends to be aware of in this population.

This study of health care access and affordability found adults with long COVID reported more unmet health care needs in the past 12 months.

New research suggests that patients with HBeAg-negative chronic hepatitis B can achieve functional cure after ending nucleoside/nucleotide analogues (NUCs) treatment.

Can anakinra reduce inflammation and the need for mechanical ventilation in patients with severe COVID-19 pneumonia?